Author

D. L. Longo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 2 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Assay:imaging· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1

Frequent Co-Authors

A. A. Anemone· 2 shared E. Terreno· 2 shared M. Capozza· 2 shared S. Aime· 2 shared S. Zullino· 2 shared A. A. Ojeda· 1 shared A. Avgustinova· 1 shared A. Bachi· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

A. A. Anemone

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

L-DOS47 enhances response to immunotherapy in pancreatic cancer tumor

B. V. Jardim-Perassi, P. Irrera, D. Abrahams, V. C. Estrella, B. Ordway, S. R. Byrne, A. A. Ojeda, C. J. Whelan, J. Kim, M. S. Beatty, S. Damgaci-Erturk, D. L. Longo, K. J. Gaspar, G. M. Siegers, B. A. Centeno, , A. Ibrahim-Hashim

This study shows that L-DOS47, a urease immunoconjugate, enhances anti-PD1 immunotherapy efficacy in pancreatic cancer by neutralizing tumor acidity.

bioRxiv · Aug 28, 2023 · PreprintCancer Biology

FADS1/2-mediated lipid metabolic reprogramming drives ferroptosis sensitivity in triple-negative breast cancer

N. Lorito, A. Subbiani, A. Smiriglia, M. Bacci, F. Bonechi, L. Tronci, A. Corrado, D. L. Longo, M. Iozzo, L. Ippolito, G. Comito, E. Giannoni, I. Meattini, A. Avgustinova, P. Chiarugi, , A. Morandi

The paper identifies FADS1/2-mediated lipid metabolic reprogramming as a driver of ferroptosis sensitivity in triple-negative breast cancer, showing that high FADS1/2 expression correlates with poor prognosis and susceptibility to ferroptosis-inducing agents.

bioRxiv · Jun 30, 2023 · PreprintCancer Biology

GlucoCEST MRI for the early evaluation response to chemotherapeutic and metabolic treatments in a murine triple negative breast cancer: a comparison with 18F-FDG-PET.

M. Capozza, A. A. Anemone, C. Dhakan, M. Della Peruta, M. Bracesco, S. Zullino, D. Villano, E. Terreno, D. L. Longo, S. Aime

This paper compares glucoCEST MRI and 18F-FDG-PET for early metabolic response monitoring in a murine TNBC model, finding glucoCEST more sensitive to treatment effects.

bioRxiv · Mar 16, 2021Biophysics

In vitro and in vivo comparison of the MRI glucoCEST properties between native glucose and 3OMG in a murine tumor model

A. A. Anemone, M. Capozza, F. Arena, S. Zullino, P. Bardini, E. Terreno, D. L. Longo, S. Aime

This study compares the MRI glucoCEST properties of native glucose and 3OMG in a murine tumor model, finding similar contrast efficiency but different temporal kinetics.

bioRxiv · Mar 15, 2021 · PreprintBiophysics